The agreement is to expand and reinforce
data-driven medicine through the SOPHiA DDM™ health data
analysis platform available with Microsoft Azure
GENEVA, Nov. 1, 2022
/PRNewswire/ -- SOPHiA GENETICS™ (Nasdaq: SOPH), a
cloud-native software company in the healthcare space, is embarking
on a multi-year integrated strategic partnership
with Microsoft to improve healthcare workflows globally. This
investment in the development of next- generation healthcare will
lead the way in enabling multimodal data curation, development, and
deployment. As a result, the Microsoft Azure-powered SOPHiA
DDM™ Platform is expected to elevate the
standard of care for patients, by delivering advanced
outcomes for precision medicine.
![The agreement is to expand and reinforce data-driven medicine through the SOPHiA DDM™️ health data analysis platform available with Microsoft Azure The agreement is to expand and reinforce data-driven medicine through the SOPHiA DDM™️ health data analysis platform available with Microsoft Azure](https://mma.prnewswire.com/media/1935064/SG_Microsoft_Partnership.jpg)
SOPHiA GENETICS' global network breaks down data silos, allowing
the democratization of data-driven medicine by connecting
institutions that leverage diverse multimodal data sets on the
SOPHiA DDM™ Platform. Multimodal health data sets
can be the largest and most complex to structure, analyze and
archive, and this wide-ranging partnership will focus on
accelerating results, improving performance, and ultimately enhance
medical research by propelling the transition to precision medicine
globally.
"With Microsoft's scale and the power of the SOPHiA DDM™
Platform, this partnership will help improve clinical outcomes and
make patient care more efficient and personalized," said Jurgi
Camblong, PhD., Co-Founder and CEO, SOPHiA
GENETICS. "SOPHiA GENETICS will help accelerate
the transition to a decentralized care model for hospitals,
healthcare providers and biopharma by breaking down data silos and
delivering innovation at scale."
"SOPHiA GENETICS' mission is to democratize data-driven
medicine. Microsoft is pleased to support this mission by providing
secure and scalable cloud infrastructure, alongside SOPHiA
GENETICS' advanced artificial intelligence and machine learning
tools and technologies that can help generate actionable insights,
which can lead to better health outcomes," said David C. Rhew, M.D., Global Chief Medical
Officer, Microsoft.
This strategic partnership expands on
SOPHiA GENETICS' and Microsoft's collaboration. SOPHiA
GENETICS offers its AI and machine learning SOPHiA DDM™ Platform on
Azure, by leveraging various Azure services that enable greater
efficiencies and open opportunities for advancing tools to unlock
important medical and genomic data. With the addition of the
SOPHiA DDM™ Platform, providers utilizing Azure will scale
their ability to aggregate multimodal data types to extract
insights within existing workflows for their pursuit to deliver the
best care possible. As one of Microsoft's chosen partners for
precision medicine, SOPHiA GENETICS will help accelerate the
transition to a decentralized care model for hospitals, healthcare
providers and biopharma, by breaking down data silos and delivering
innovation at scale.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to
obtain the appropriate product information for your country of
residence.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated
to establishing the practice of data-driven medicine as the
standard of care and for life sciences research. It is the creator
of the SOPHiA DDM™ Platform, a cloud-native platform capable of
analyzing data and generating insights from complex multimodal data
sets and different diagnostic modalities. The SOPHiA DDM™ Platform
and related solutions, products and services are currently used by
a broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect
on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/sophia-genetics-partners-with-microsoft-to-accelerate-multimodal-health-data-analysis-301664804.html
SOURCE SOPHiA GENETICS